Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome
Stopped early · Phase 3 · Has a placebo group
Conditions studied: Myelodysplastic Syndromes
In brief
This study compares the efficacy of Tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syndrome (HR-MDS), and who have not received treatment for this diagnosis. The primary goal of the study is to compare the complete remission rate between the two treatment arms.
Key facts
- Study ID
- NCT04797780
- Run by
- Syros Pharmaceuticals
- People needed
- 246
- Starts
- 2021-02-08
- Expected to finish
- 2024-11-13
- Last updated by the study team
- 2025-04-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Southern California — Los Angeles, California, United States
- University of California, Los Angelas — Los Angeles, California, United States
- Yale Cancer Center — New Haven, Connecticut, United States
- Comprehensive Hematology and Oncology — St. Petersburg, Florida, United States
- Moffitt Cancer Center — Tampa, Florida, United States
- University of Illinois Cancer Center — Chicago, Illinois, United States
- Orchard Healthcare Research Inc. — Skokie, Illinois, United States
- University of Iowa — Iowa City, Iowa, United States
- Tulane Cancer Center — New Orleans, Louisiana, United States
- Johns Hopkins University — Baltimore, Maryland, United States
- American Oncology Partners of Maryland, PA — Bethesda, Maryland, United States
- Morristown Medical Center- Atlantic Hematology Oncology — Morristown, New Jersey, United States
- Northwell Health — Lake Success, New York, United States
- Novant Health Inc — Charlotte, North Carolina, United States
- Novant Health Cancer Institute - Forsyth — Winston-Salem, North Carolina, United States
- Wake Forest Baptist Health — Winston-Salem, North Carolina, United States
- The Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States
- Oregon Health and Science University — Portland, Oregon, United States
- TriStar - Sarah Cannon BMT — Nashville, Tennessee, United States
- University of Utah Huntsman Cancer Institute — Salt Lake City, Utah, United States
- Swedish Cancer Institute — Seattle, Washington, United States
- Medical University of Graz — Graz, Austria
- Salzburg Cancer Research Institute (SCRI) — Salzburg, Austria
- Klinik Hietzing — Vienna, Austria
- University of Arizona — Tucson, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.